File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0928-8244(99)00130-3
- Scopus: eid_2-s2.0-0032853186
- PMID: 10536299
- WOS: WOS:000083484600005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: The effect of orally administered viable probiotic and dairy lactobacilli on mouse lymphocyte proliferation
Title | The effect of orally administered viable probiotic and dairy lactobacilli on mouse lymphocyte proliferation |
---|---|
Authors | |
Keywords | Immunomodulation Lactobacillus Lymphocyte proliferation Mitogen cytotoxicity Oral administration Probiotic bacterium |
Issue Date | 1999 |
Publisher | Blackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journal.asp?ref=0928-8244&site=1 |
Citation | Fems Immunology And Medical Microbiology, 1999, v. 26 n. 2, p. 131-135 How to Cite? |
Abstract | Four common Lactobacillus strains were screened for their effects on proliferation of mouse splenic lymphocytes. Mice received perorally 109 viable bacteria kg-1 body weight for 7 days. Lactobacillus acidophilus treatment enhanced ex vivo basal proliferation (by 43%) and B-cell response at suboptimal and optimal concentrations of lipopolysaccharide (LPS) (by 27-28%). Conversely, Lactobacillus casei, Lactobacillus gasseri and Lactobacillus rhamnosus inhibited both basal proliferation (by 14-51%) and mitogen-stimulated lymphoproliferation, particularly at supra-optimal concentrations of concanavalin A (by 43-68%) and LPS (by 23-62%). Therefore, these Lactobacillus strains demonstrate strain-specific effects on B- and T-cells and may also alter the splenocyte sensitivity to the cytotoxic effects of mitogens. Copyright (C) 1999 Federation of European Microbiological Societies. |
Persistent Identifier | http://hdl.handle.net/10722/178655 |
ISSN | 2014 Impact Factor: 3.078 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kirjavainen, PV | en_US |
dc.contributor.author | ElNezami, HS | en_US |
dc.contributor.author | Salminen, SJ | en_US |
dc.contributor.author | Ahokas, JT | en_US |
dc.contributor.author | Wright, PFA | en_US |
dc.date.accessioned | 2012-12-19T09:48:58Z | - |
dc.date.available | 2012-12-19T09:48:58Z | - |
dc.date.issued | 1999 | en_US |
dc.identifier.citation | Fems Immunology And Medical Microbiology, 1999, v. 26 n. 2, p. 131-135 | en_US |
dc.identifier.issn | 0928-8244 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/178655 | - |
dc.description.abstract | Four common Lactobacillus strains were screened for their effects on proliferation of mouse splenic lymphocytes. Mice received perorally 109 viable bacteria kg-1 body weight for 7 days. Lactobacillus acidophilus treatment enhanced ex vivo basal proliferation (by 43%) and B-cell response at suboptimal and optimal concentrations of lipopolysaccharide (LPS) (by 27-28%). Conversely, Lactobacillus casei, Lactobacillus gasseri and Lactobacillus rhamnosus inhibited both basal proliferation (by 14-51%) and mitogen-stimulated lymphoproliferation, particularly at supra-optimal concentrations of concanavalin A (by 43-68%) and LPS (by 23-62%). Therefore, these Lactobacillus strains demonstrate strain-specific effects on B- and T-cells and may also alter the splenocyte sensitivity to the cytotoxic effects of mitogens. Copyright (C) 1999 Federation of European Microbiological Societies. | en_US |
dc.language | eng | en_US |
dc.publisher | Blackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journal.asp?ref=0928-8244&site=1 | en_US |
dc.relation.ispartof | FEMS Immunology and Medical Microbiology | en_US |
dc.subject | Immunomodulation | - |
dc.subject | Lactobacillus | - |
dc.subject | Lymphocyte proliferation | - |
dc.subject | Mitogen cytotoxicity | - |
dc.subject | Oral administration | - |
dc.subject | Probiotic bacterium | - |
dc.subject.mesh | Adjuvants, Immunologic - Administration & Dosage - Pharmacology | en_US |
dc.subject.mesh | Administration, Oral | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Cell Division | en_US |
dc.subject.mesh | Concanavalin A - Pharmacology | en_US |
dc.subject.mesh | Lactobacillus | en_US |
dc.subject.mesh | Lactobacillus Acidophilus | en_US |
dc.subject.mesh | Lactobacillus Casei | en_US |
dc.subject.mesh | Lipopolysaccharides - Pharmacology | en_US |
dc.subject.mesh | Lymphocytes - Cytology | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Mice | en_US |
dc.subject.mesh | Mitogens - Pharmacology | en_US |
dc.subject.mesh | Probiotics - Administration & Dosage - Pharmacology | en_US |
dc.subject.mesh | Species Specificity | en_US |
dc.subject.mesh | Spleen - Cytology | en_US |
dc.title | The effect of orally administered viable probiotic and dairy lactobacilli on mouse lymphocyte proliferation | en_US |
dc.type | Article | en_US |
dc.identifier.email | ElNezami, HS: elnezami@hkucc.hku.hk | en_US |
dc.identifier.authority | ElNezami, HS=rp00694 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/S0928-8244(99)00130-3 | en_US |
dc.identifier.pmid | 10536299 | - |
dc.identifier.scopus | eid_2-s2.0-0032853186 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0032853186&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 26 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.spage | 131 | en_US |
dc.identifier.epage | 135 | en_US |
dc.identifier.isi | WOS:000083484600005 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Kirjavainen, PV=6701800774 | en_US |
dc.identifier.scopusauthorid | ElNezami, HS=6603690577 | en_US |
dc.identifier.scopusauthorid | Salminen, SJ=7102912002 | en_US |
dc.identifier.scopusauthorid | Ahokas, JT=7006308329 | en_US |
dc.identifier.scopusauthorid | Wright, PFA=7404315992 | en_US |
dc.identifier.issnl | 0928-8244 | - |